Try our beta test site
599 studies found for:    peptide vaccine
Show Display Options
Rank Status Study
1 Recruiting Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
Condition: Glioma
Intervention: Drug: IDH1 peptide vaccine
2 Active, not recruiting Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention: Biological: WT1 peptide vaccine
3 Not yet recruiting Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Conditions: Bilateral Breast Carcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma;   Unilateral Breast Carcinoma
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine;   Other: Placebo;   Biological: Sargramostim
4 Not yet recruiting Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Nivolumab;   Biological: PD-L1/IDO peptide vaccine
5 Unknown  Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection
Condition: Vaccine Overdose of Undetermined Intent
Interventions: Biological: prophylactic peptide vaccine;   Biological: therapeutic peptide vaccine
6 Recruiting A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Biological: 6MHP
7 Enrolling by invitation Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Conditions: Pancreatic Cancer;   Colorectal Cancer
Interventions: Biological: Peptide Vaccine;   Behavioral: Phone Call
8 Completed
Has Results
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Condition: Leukemia
Interventions: Biological: WT-1;   Drug: Montanide;   Drug: Sargramostim (GM-CSF)
9 Active, not recruiting Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Biological: E39 peptide vaccine;   Biological: E39 vaccine then J65 vaccine;   Biological: J65 vaccine then E39 vaccine
10 Completed A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
Condition: HIV Infections
Intervention: Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine
11 Recruiting Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Montanide ISA-51;   Drug: polyICLC;   Drug: Cyclophosphamide
12 Completed Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
Condition: Melanoma
Interventions: Drug: Pegylated Interferon-Alfa 2b (PEG Intron);   Drug: GP-100 Peptide Vaccine
13 Recruiting A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
Condition: Melanoma
Interventions: Drug: dabrafenib;   Biological: 6MHP;   Drug: Trametinib
14 Completed A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Interventions: Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent;   Biological: rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
15 Completed A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
16 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
17 Active, not recruiting
Has Results
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Interventions: Biological: Peptide Vaccine;   Drug: Poly IC-LC
18 Recruiting Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Pembrolizumab
19 Unknown  Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: antiangiogenic paptide vaccine
20 Active, not recruiting H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Glioma
Intervention: Biological: K27M peptide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.